Lord, Abbett & Co’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-523,972
| Closed | -$125M | – | 543 |
|
|
2022
Q4 | $125M | Buy |
523,972
+4,840
| +0.9% | +$1.15M | 0.45% | 51 |
|
|
2022
Q3 | $104M | Buy |
+519,132
| New | +$104M | 0.38% | 68 |
|
|
2022
Q1 | – | Sell |
-42,000
| Closed | -$7.12M | – | 602 |
|
|
2021
Q4 | $7.12M | Sell |
42,000
-238,000
| -85% | -$40.4M | 0.02% | 527 |
|
|
2021
Q3 | $52.9M | Buy |
+280,000
| New | +$52.9M | 0.13% | 250 |
|
|
2018
Q2 | – | Sell |
-297,210
| Closed | -$35.4M | – | 843 |
|
|
2018
Q1 | $35.4M | Buy |
297,210
+40,408
| +16% | +$4.81M | 0.11% | 302 |
|
|
2017
Q4 | $32.6M | Buy |
256,802
+141,050
| +122% | +$17.9M | 0.09% | 337 |
|
|
2017
Q3 | $13.6M | Buy |
+115,752
| New | +$13.6M | 0.04% | 557 |
|
|
2015
Q3 | – | Sell |
-133,584
| Closed | -$16M | – | 901 |
|
|
2015
Q2 | $16M | Sell |
133,584
-209,734
| -61% | -$25.1M | 0.04% | 542 |
|
|
2015
Q1 | $35.8M | Buy |
343,318
+59,027
| +21% | +$6.16M | 0.09% | 345 |
|
|
2014
Q4 | $27.6M | Sell |
284,291
-407,656
| -59% | -$39.5M | 0.07% | 394 |
|
|
2014
Q3 | $54M | Sell |
691,947
-51,724
| -7% | -$4.04M | 0.14% | 195 |
|
|
2014
Q2 | $47M | Buy |
743,671
+601,719
| +424% | +$38M | 0.11% | 271 |
|
|
2014
Q1 | $9.53M | Sell |
141,952
-177,610
| -56% | -$11.9M | 0.02% | 656 |
|
|
2013
Q4 | $20.6M | Sell |
319,562
-264,543
| -45% | -$17M | 0.05% | 525 |
|
|
2013
Q3 | $37.4M | Sell |
584,105
-442,397
| -43% | -$28.3M | 0.09% | 341 |
|
|
2013
Q2 | $31.8M | Buy |
+1,026,502
| New | +$31.8M | 0.07% | 399 |
|